Moderna Hires Harvard Stem Cell Researcher Jonathan Hoggatt as Director of Hematology: What You Need to Know
Moderna, Inc. (NASDAQ: MRNA), which shot to prominence with its coronavirus vaccine program, is beefing up its research and development team.
What Happened: Jonathan Hoggatt, who was a principal faculty member at Harvard Stem Cell Institute, has joined Cambridge, Massachusetts-based Moderna as director of hematology, according to a Twitter post by the researcher.
Happy to announce that I have joined @moderna_tx as the new Director of Hematology. Will be forming a team and working to make new therapies for hematology patients in need. Bittersweet to leave academia and my lab, but excited about the platform and potential to help patients.
— Jonathan Hoggatt (@jghoggatt) March 4, 2021
He served as assistant professor at the Harvard Medical School's Hoggatt Lab, which works on tissue regeneration and stem cell biology, with a particular focus on translational research to enhance bone marrow transplantation.
Hoggatt has a master's degree in biology and a doctoral degree in hematology, and pursued a post-doctoral program in stem cell biology, his LinkedIn profile revealed.
Related Link: The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Why It's Important: After the resounding success with its coronavirus vaccine program, it's logical Moderna now turns its attention toward other programs.
The company has a rich pipeline, comprising investigational prophylactic vaccines against infectious diseases, secreted and cell therapeutic candidates, cancer vaccine candidates, regenerative therapeutic candidates and immuno-oncology candidates.
The immuno-oncology pipeline consists of two candidates, namely mRNA-2416 for lymphoma and a triplet candidate, codenamed mRNA-2752, both aimed at treating lymphoma and solid tumors.
The new appointment may be signaling Moderna's intent to focus on these candidates in a big way.
MRNA Price Action: In premarket trading Friday, Moderna shares were slipping 1.36% to $130.50.
Related Link: The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study
(Moderna's Cambridge, Massachusetts offices; photo by Fletcher via Wikimedia Commons)
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
